A germline oncogenic MITF mutation and tumor susceptibility

European Journal of Cell Biology

Volumn 93, Issue 1-2, 2014, Pages 71-75

  Paillerets, Brigitte Bressac de ^a,b   Lesueur, Fabienne ^c   Bertolotto, Corine ^a,d  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSERM U900   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Melanoma; MITF; Mutation

Indexed keywords

LAMIN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

BINDING SITE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONSENSUS SEQUENCE; CUTANEOUS MELANOMA; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY CARCINOMA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR GENE; MISSENSE MUTATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SUMOYLATION; TFE3 GENE; TFEB GENE; COMPLICATION; GENETICS; GERMLINE MUTATION; KIDNEY TUMOR; MELANOMA; PATHOLOGY; SKIN TUMOR;

CARCINOGENESIS; CARCINOMA, RENAL CELL; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; KIDNEY NEOPLASMS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; SKIN NEOPLASMS; SUMOYLATION;

EID: 84897502128     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2013.10.002     Document Type: Short Survey

References (55)

1. Argani P., Lui M.Y., Couturier J., Bouvier R., Fournet J.C., Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 2003, 22:5374-5378.
2. Bawa-Khalfe T., Yeh E.T. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010, 1:748-752.
3. Beisland C., Talleraas O., Bakke A., Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006, 97:698-702.
4. Bertolotto C., Abbe P., Hemesath T.J., Bille K., Fisher D.E., Ortonne J.P., Ballotti R. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell. Biol. 1998, 142:827-835.
5. Bertolotto C., Bille K., Ortonne J.P., Ballotti R. Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: implication of the microphthalmia gene product. J. Cell Biol. 1996, 134:747-755.
6. Bertolotto C., Busca R., Abbe P., Bille K., Aberdam E., Ortonne J.P., Ballotti R. Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. Mol. Cell Biol. 1998, 18:694-702.
7. Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M., Bille K., Dessen P., d'Hayer B., Mohamdi H., Remenieras A., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98.
8. Beuret L., Ohanna M., Strub T., Allegra M., Davidson I., Bertolotto C., Ballotti R. BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res. 2011, 24:725-727.
9. Bradford P.T., Freedman D.M., Goldstein A.M., Tucker M.A. Increased risk of second primary cancers after a diagnosis of melanoma. Arch. Dermatol. 2010, 146:265-272.
10. Bressac-de-Paillerets B., Avril M.F., Chompret A., Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002, 84:67-74.
11. Busca R., Berra E., Gaggioli C., Khaled M., Bille K., Marchetti B., Thyss R., Fitsialos G., Larribere L., Bertolotto C., et al. Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 2005, 170:49-59.
12. Carreira S., Goodall J., Denat L., Rodriguez M., Nuciforo P., Hoek K.S., Testori A., Larue L., Goding C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006, 20:3426-3439.
13. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010, 23:27-40.
14. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
15. Cronin J.C., Wunderlich J., Loftus S.K., Prickett T.D., Wei X., Ridd K., Vemula S., Burrell A.S., Agrawal N.S., Lin J.C., et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 2009, 22:435-444.
16. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
17. Davis I.J., Fisher D.E. MiT transcription factor associated malignancies in man. Cell Cycle 2007, 6:1724-1729.
18. Davis I.J., Hsi B.L., Arroyo J.D., Vargas S.O., Yeh Y.A., Motyckova G., Valencia P., Perez-Atayde A.R., Argani P., Ladanyi M., et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6051-6056.
19. Davis I.J., Kim J.J., Ozsolak F., Widlund H.R., Rozenblatt-Rosen O., Granter S.R., Du J., Fletcher J.A., Denny C.T., Lessnick S.L., et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006, 9:473-484.
20. Fargnoli M.C., Gandini S., Peris K., Maisonneuve P., Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur. J. Cancer 2010, 46:1413-1420.
21. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
22. Ghiorzo P., Pastorino L., Queirolo P., Bruno W., Tibiletti M.G., Nasti S., Andreotti V., Paillerets B.B., Bianchi Scarra G. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res. 2013, 26:259-262.
23. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., Dow S., Lucau-Danila A., Anderson K., Andre B., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002, 418:387-391.
24. Giuliano S., Cheli Y., Ohanna M., Bonet C., Beuret L., Bille K., Loubat A., Hofman V., Hofman P., Ponzio G., et al. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res. 2010, 70:3813-3822.
25. Giuliano S., Ohanna M., Ballotti R., Bertolotto C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 2011, 24:295-308. (in press).
26. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
27. Hou L., Panthier J.J., Arnheiter H. Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development 2000, 127:5379-5389.
28. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.S., Sheahan M.D., Clark W.H., Tucker M.A., Dracopoli N.C. Germline p16 mutations in familial melanoma. Nat. Genet. 1994, 8:15-21.
29. Kim E.Y., Chen L., Ma Y., Yu W., Chang J., Moskowitz I.P., Wang J. Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects. PloS one 2011, 6:e20803.
30. Law M.H., Macgregor S., Hayward N.K. Melanoma genetics: recent findings take us beyond well-traveled pathways. J. Invest. Dermatol. 2012, 132:1763-1774.
31. Linehan W.M., Bratslavsky G., Pinto P.A., Schmidt L.S., Neckers L., Bottaro D.P., Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 2010, 61:329-343.
32. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
33. Maubec E., Chaudru V., Mohamdi H., Grange F., Patard J.J., Dalle S., Crickx B., Paillerets B.B., Demenais F., Avril M.F. Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer 2010, 116:5716-5724.
34. Miller A.J., Levy C., Davis I.J., Razin E., Fisher D.E. Sumoylation of MITF and its related family members TFE3 and TFEB. J. Biol. Chem. 2005, 280:146-155.
35. Mo Y.Y., Yu Y., Theodosiou E., Ee P.L., Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 2005, 24:2677-2683.
36. Morris J.R., Boutell C., Keppler M., Densham R., Weekes D., Alamshah A., Butler L., Galanty Y., Pangon L., Kiuchi T., et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009, 462:886-890.
37. Murakami H., Arnheiter H. Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res. 2005, 18:265-277.
38. Nacerddine K., Lehembre F., Bhaumik M., Artus J., Cohen-Tannoudji M., Babinet C., Pandolfi P.P., Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 2005, 9:769-779.
39. Nishimura E.K., Granter S.R., Fisher D.E. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 2004.
40. Pingault V., Ente D., Dastot-Le Moal F., Goossens M., Marlin S., Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum. Mutat. 2010, 31:391-406.
41. Sarge K.D., Park-Sarge O.K. SUMO and its role in human diseases. Int. Rev. Cell Mol. Biol. 2011, 288:167-183.
42. Schmid-Wendtner M.H., Baumert J., Wendtner C.M., Plewig G., Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br. J. Dermatol. 2001, 145:981-985.
43. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
44. Steingrimsson E., Copeland N.G., Jenkins N.A. Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 2004, 38:365-411.
45. Steingrimsson E., Tessarollo L., Pathak B., Hou L., Arnheiter H., Copeland N.G., Jenkins N.A. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Int. Proc. Natl. Acad. Sci. U.S.A. 2002, 4477-4482.
46. Strub T., Giuliano S., Ye T., Bonet C., Keime C., Kobi D., Le Gras S., Cormont M., Ballotti R., Bertolotto C., et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 2011, 30:2319-2332.
47. Sturm R.A., Fox C., McClenahan P., Jagirdar K., Ibarrola-Villava M., Banan P., Abbott N.C., Ribas G., Gabrielli B., Duffy D.L., et al. Phenotypic characterization of Nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J. Invest. Dermatol. 2013.
48. Tsuda M., Davis I.J., Argani P., Shukla N., McGill G.G., Nagai M., Saito T., Lae M., Fisher D.E., Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007, 67:919-929.
49. Wang X.D., Lapi E., Sullivan A., Ratnayaka I., Goldin R., Hay R., Lu X. SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Diff. 2011, 18:304-314.
50. Weterman M.J., van Groningen J.J., Jansen A., van Kessel A.G. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 2000, 19:69-74.
51. Wilkinson K.A., Henley J.M. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 2010, 428:133-145.
52. Wu Y.H., Kim G.H., Wagner J.D., Hood A.F., Chuang T.Y. The association between malignant melanoma and noncutaneous malignancies. Int. J. Dermatol. 2006, 45:529-534.
53. Yokoyama S., Woods S.L., Boyle G.M., Aoude L.G., MacGregor S., Zismann V., Gartside M., Cust A.E., Haq R., Harland M., et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
54. Zhang Y.Q., Sarge K.D. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J. Cell Biol. 2008, 182:35-39.
55. Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J., Hayward N., Dracopoli N.C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 1996, 12:97-99.